Nolvadex (Tamoxifen) 20-10mg
Ten-year course of tamoxifen was more effective than five years. Twofold prolongation of tamoxifen daily administration of the drug, with five to ten years, reduces the risk of recurrence and mortality in patients with estrogen-dependent breast cancer, particularly during the subsequent decade after withdrawal of the drug.
Tamoxifen (Nolvadex) - an antagonist of the female sex hormone estrogen. The drugs are based on the ability to bind to hormonal receptors on the surface of tumor cells and block their connection to the natural estrogen, thereby suppressing the stimulating effect exerted on the tumor hormone. Tamoxifen is typically given to premenopausal women who have had estrogen-dependent breast cancer, in order to minimize the risk of disease recurrence, as well as being in a group at high risk for the disease as a preventive measure.
It has already been shown that the effectiveness of tamoxifen increases with duration of use and the drug began to appoint not two years after diagnosis, and the five that decreased mortality among patients in the subsequent decade after discontinuation. The new study was designed to examine the effects of more long-term use of the drug.
It should be noted that tamoxifen is the treatment of first-line patients only in premenopausal women. Women with estrogen-dependent breast cancer in post-menopausal usually prescribe another type of hormone therapy - a five-year course of an aromatase inhibitors, sometimes in combination with tamoxifen. By aromatase inhibitors are Aromasin (exemestane), Arimidex (anastrozole) and Femara (letrazole). Buy cheap Tamoxifen in India.
Ten-year course of tamoxifen was more effective than five years. Twofold prolongation of tamoxifen daily administration of the drug, with five to ten years, reduces the risk of recurrence and mortality in patients with estrogen-dependent breast cancer, particularly during the subsequent decade after withdrawal of the drug.
Tamoxifen - an antagonist of the female sex hormone estrogen. The drugs are based on the ability to bind to hormonal receptors on the surface of tumor cells and block their connection to the natural estrogen, thereby suppressing the stimulating effect exerted on the tumor hormone. Tamoxifen is typically given to premenopausal women who have had estrogen-dependent breast cancer, in order to minimize the risk of disease recurrence, as well as being in a group at high risk for the disease as a preventive measure.
It has already been shown that the effectiveness of tamoxifen increases with duration of use and the drug began to appoint not two years after diagnosis, and the five that decreased mortality among patients in the subsequent decade after discontinuation. The new study was designed to examine the effects of more long-term use of the drug.
It should be noted that tamoxifen is the treatment of first-line patients only in premenopausal women. Women with estrogen-dependent breast cancer in post-menopausal usually prescribe another type of hormone therapy - a five-year course of an aromatase inhibitors, sometimes in combination with tamoxifen. By aromatase inhibitors are Aromasin (exemestane), Arimidex (anastrozole) and Femara (letrazole).